MedTrace Logo

Using ctDNA to Detect Minimal Residual Disease After Lung Cancer Resection

NCT05254782 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 360

Last updated 2024-12-06

No results posted yet for this study

Summary

ctDNALung-Detect is an investigator-initiated single arm, multi-institution study designed to assess the ctDNA detection rate and its association with Relapse Free Survival (RFS) in operable stage T1-T4 (T3,T4 multifocal) N0M0 non-small cell lung cancer (NSCLC) patients.

Conditions

  • Non Small Cell Lung Cancer

Sponsors & Collaborators

  • Ontario Institute for Cancer Research

    collaborator OTHER

  • The Princess Margaret Cancer Foundation

    collaborator OTHER

  • University Health Network, Toronto

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-06
Primary Completion
2026-03-30
Completion
2027-03-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05254782 on ClinicalTrials.gov